Adia Nutrition Stock Price, News & Analysis

Adia Nutrition (OTCQB: ADIA) announced that independent IRB BeyondBound approved its patent-pending clinical study protocol for an Autism Spectrum Disorder (ASD) trial run by Adia Med of Winter Park LLC.

The randomized study will enroll 100 children ages 3–12 to compare combined glutathione plus umbilical cord blood-derived stem cells versus glutathione alone. Key outcomes include social interaction, communication, behavior, and quality of life.

Patient recruitment is expected to begin in January 2026. Study details have been submitted to ClinicalTrials.gov and are in final review before public posting.

Adia Nutrition (OTCQB: ADIA) filed a Form 10 registration statement with the U.S. Securities and Exchange Commission on December 8, 2025, prepared with assistance from the company's CFO, auditing accountant, corporate accountant, and legal counsel.

The filing is a strategic step toward full reporting status; once the Form 10 becomes effective (expected ~60 days after submission), Adia will begin reporting under the Securities Exchange Act of 1934 with audited financials and regular annual and quarterly disclosures. The company said Form 10 does not guarantee immediate national exchange listing such as Nasdaq and expects to announce effectiveness in early 2026. Filing materials are available on EDGAR.

Adia Med (OTCQB: ADIA) announced a media partnership with 3X physician and talk-show host Dr. Asa Andrew and The Dr. Asa Network on December 1, 2025. The agreement names Dr. Asa as an official media partner, spokesperson, and content creator for Adia Med to produce exclusive digital, social, radio, TV, podcast, and docu-series content focused on stem cell therapies and longevity medicine. Leadership states the partnership aims to increase awareness, education, and access to Adia Med's regenerative treatments and to support clinic licensing and strategic partnerships.

ADIA Nutrition (OTCQB: ADIA) submitted its complete, patent-pending regenerative protocol for pediatric Autism Spectrum Disorder to an independent Institutional Review Board on November 24, 2025 after the IRB accepted the company's initial draft and invited a final version.

The filing includes detailed methodology, safety measures, dosing regimen, and clinical endpoints and is under expert evaluation; IRB acceptance would authorize ADIA's first-ever IRB-approved human study using antioxidants and stem cells in children with ASD. The protocol remains confidential while intellectual property and clinical pathways advance; the company said a larger update will follow the IRB determination.

ADIA Nutrition (OTCQB: ADIA) will host a live webinar on Thursday, November 20, 2025 at 6:30 PM EST on Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis and other autoimmune conditions.

Dr. Evan Thomas, MD, PhD, medical director of Adia Med HSCT Program, will discuss the science, patient outcomes, and Adia Med’s physician-led approach. Registration is available via Zoom and interested parties can contact CEO Larry Powalisz for more information or partnership inquiries.

ADIA Nutrition (OTCQB: ADIA) filed with the SEC and OTC Markets on November 17, 2025 to update its Standard Industrial Classification to 2836 (Biological Products, Except Diagnostic), replacing prior codes 2834 and 6719 to better reflect its biologics manufacturing and clinic operations.

The company noted Adia Labs sells FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink) nationwide and Adia Med clinics provide regenerative treatments. The change will take effect on ADIA's next filings. ADIA also highlighted 200%+ Q3 2025 revenue growth, OTCQB uplisting progress, and an expanding clinic network.

ADIA Nutrition (OTCQB: ADIA) filed a provisional patent application with the United States Patent and Trademark Office on November 12, 2025 for a novel medical protocol aimed at enhancing regenerative outcomes.

The patent pending protocol reportedly uses unique procedural and biological mechanisms and gives ADIA a 12-month window to advance research, partnerships, and commercialization while preserving strategic confidentiality.

The company invited clinic owners and healthcare practitioners to inquire about licensing and integration of its regenerative therapies and said further updates will follow as development progresses.

Adia Nutrition (OTCQB: ADIA) announced a strategic partnership between its research arm Adia Labs and AxiaMD on November 10, 2025.

Under the agreement, AxiaMD's nationwide physician-oversight network will offer Adia Labs' regenerative products to clients while Adia's clinics gain AxiaMD's compliance and oversight services across all 50 states, enabling chiropractic clinics to perform advanced regenerative procedures under full physician oversight. The release highlights FDA-compliant stem cell products, a mutual referral model, and prior company momentum including 200%+ Q3 2025 revenue growth and an OTCQB uplisting toward Nasdaq eligibility.

Adia Nutrition (OTCQB: ADIA) summarized 2025 milestones including a confirmed 200%+ Q3 revenue surge quarter-over-quarter with profit margins above 20%, accelerated commercial expansion, and steps toward Nasdaq uplisting. The company said it will file a Form 10 by end of November 2025 (SEC review period ~60 days) and expects Form 10 effectiveness by late January 2026. Other highlights: sales force tripled with four regional divisions, preferred‑vendor access to >4,000 personal injury physicians, progress toward insurer in‑network status, and a divestiture of Biolete Coffee while retaining an 18% equity stake.